Philip Coelho - Ampio Pharm Chairman
| AMPEDelisted Stock | USD 0.25 0.10 28.57% |
Chairman
Mr. Philip H. Coelho, M.D., is the Independent Director of Ampio Pharmaceuticals, Inc., since 2010. Mr. Coelho has served as a member of our Board of Directors since April 2010. Mr. Coelho was in the senior management of high technology consumer electronic or medical device companies for over 30 years. Mr. Coelho is the Chief Technology Officer and CoFounder of SynGen Inc., a firm inventing and commercializing products that harvest stem and progenitor cells derived from a donor or the patients own body to treat human disease. Prior to founding SynGen Inc. in October 2009, Mr. Coelho was the President and CEO of PHC Medical, Inc., a consulting firm, from August 2008 through October 2009. From August 2007 through May 2008, Mr. Coelho served as the Chief Technology Architect of ThermoGenesis Corporationration, a medical products company he founded in 1986 that focused on the regenerative medicine market. From 1989 through July 2007, he was Chairman and CEO of ThermoGenesis Corporationration Mr. Coelho served as Vice President of Research Development of ThermoGenesis from 1986 through 1989. He was President of Castleton Inc. from 1982 to 1986, and President of ESS Inc. from 1971 to 1982. Mr. Coelho also serves as a member of the board of directors of NASDAQlisted company, Catalyst Pharmaceuticals Partners, Inc., and served as a member of the Board of Directors of NASDAQlisted Mediware Information Systems, Inc. since 2010.
| Age | 74 |
| Tenure | 14 years |
| Phone | 720 437 6500 |
| Web | https://ampiopharma.com |
Ampio Pharm Management Efficiency
The company has return on total asset (ROA) of (0.6157) % which means that it has lost $0.6157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1396) %, meaning that it created substantial loss on money invested by shareholders. Ampio Pharm's management efficiency ratios could be used to measure how well Ampio Pharm manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | CHAIRMAN Age | ||
| Douglas Williams | AC Immune | 59 | |
| Michael Powell | Synlogic | 62 | |
| Mitchell Gold | Alpine Immune Sciences | 50 | |
| Mark Iwicki | Pulmatrix | 51 | |
| Robert Bitterman | Phio Pharmaceuticals Corp | 73 | |
| Ray Prudo | Akari Therapeutics PLC | N/A | |
| Stephen Glover | ZyVersa Therapeutics | 64 | |
| Joseph Swedish | AN2 Therapeutics | 65 | |
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
| Martin Velasco | AC Immune | 62 | |
Management Performance
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.62 |
Ampio Pharm Leadership Team
Elected by the shareholders, the Ampio Pharm's board of directors comprises two types of representatives: Ampio Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ampio. The board's role is to monitor Ampio Pharm's management team and ensure that shareholders' interests are well served. Ampio Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ampio Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Corp CFO | ||
| Laura Goldberg, VP Operations | ||
| Daniel Stokely, CFO, Corporate Secretary | ||
| MBBCh MMM, Chief Officer | ||
| Holli Cherevka, COO | ||
| David Stevens, Independent Director | ||
| Daniel CPA, Corporate CFO | ||
| Lane Hapke, VP Operations | ||
| April Ramirez, Clinical Manager | ||
| Michael Martino, CEO Director | ||
| Michael MacAluso, Founder, Chairman and CEO | ||
| Thomas Chilcott, Interim CFO | ||
| Vaughan Clift, Chief Regulatory Affairs Officer | ||
| Philip Coelho, Director, Chairman of Compensation Committee, Chairman of Nominating and Governance Committee and Member of Audit Committee | ||
| Richard Giles, Director of Investor Relations, Director, Chairman of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation Committee | ||
| Gregory Gould, CFO, Treasurer, Corporate Secretary | ||
| David BarOr, Chief Scientific Officer, Director | ||
| David MD, Founder Board |
Ampio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ampio Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | (3.33 M) | ||||
| Shares Outstanding | 1.14 M | ||||
| Shares Owned By Insiders | 1.56 % | ||||
| Shares Owned By Institutions | 4.19 % | ||||
| Number Of Shares Shorted | 32.9 K | ||||
| Price To Earning | 28.57 X | ||||
| Price To Book | 0.21 X | ||||
| EBITDA | (8.63 M) |
Pair Trading with Ampio Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ampio Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ampio Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Ampio Pink Sheet
| 0.67 | DMAC | DiaMedica Therapeutics Financial Report 20th of May 2024 | PairCorr |
Moving against Ampio Pink Sheet
| 0.84 | VERU | Veru Inc Financial Report 9th of May 2024 | PairCorr |
| 0.82 | DOMH | Dominari Holdings | PairCorr |
| 0.79 | YS | YS Biopharma | PairCorr |
The ability to find closely correlated positions to Ampio Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ampio Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ampio Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ampio Pharm to buy it.
The correlation of Ampio Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ampio Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ampio Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ampio Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ampio Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Ampio Pink Sheet
If you are still planning to invest in Ampio Pharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ampio Pharm's history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |